GlassScriptPhysician profile
Ronald E South
NPI 1457314577
$58,877.08
in general payments reported to CMS, 2019-2025
53 companies · $19K in 2025
The $19K reported for 2025 was more than what 92% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $862 · 2020: $1,778 · 2021: $1,965 · 2022: $1,963 · 2023: $1,866 · 2024: $32K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $28K · Consulting Fee: $11K · Food and Beverage: $8,842 · Travel and Lodging: $4,360 · Education: $59.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $27,557.50 |
| Consulting Fee | $11,489.50 |
| Food and Beverage | $8,842.03 |
| Travel and Lodging | $4,360.12 |
| Education | $59.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $45,114.71 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,563.37 | 2019-2025 | |
| Abbvie INC. | $1,165.39 | 2021-2025 | Qulipta, Ubrelvy, Duopa |
| Ucb, INC. | $782.58 | 2019-2025 | Rystiggo, Briviact, Nayzilam |
| Mdd US Operations, LLC | $781.29 | 2022-2025 | Gocovri, Apokyn, Xadago |
| Amgen INC. | $686.26 | 2019-2025 | Uplizna, Aimovig |
| Csl Behring | $648.99 | 2019-2025 | Hizentra |
| Neurocrine Biosciences, INC. | $613.93 | 2020-2025 | Ingrezza, Ongentys |
| Emd Serono, INC. | $576.89 | 2020-2023 | Mavenclad |
| Biogen, INC. | $540.73 | 2019-2025 | Vumerity, Tysabri |
| Lilly USA, LLC | $506.04 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Pfizer INC. | $466.90 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $466.46 | 2019-2024 | Austedo Xr, Ajovy |
| Sunovion Pharmaceuticals INC. | $439.69 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $427.73 | 2020-2025 | Rytary, Crexont |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald South listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.